Skip to content

US · XFOR · BIOTECHNOLOGY

X4 Pharmaceuticals, Inc. (XFOR) intrinsic value and stock valuation

$3.00as of 2026-11-21 · Mkt cap 391.43M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

X4 Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values XFOR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XFOR’s statements →

X4 Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02134 x4pharma.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$35.1M+63.6% 5y CAGRd
20152025
Net income
-$-79.2M
20152025
Free cash flow
-$-88.62M
20152025
Total equity
$186.3M+20.7% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$35.1M$2.56M$0.00$0.00$0.00
Operating income-$-86.88M-$-36.4M-$-107.52M-$-87.57M-$-75.35M
Net income-$-79.2M-$-37.45M-$-101.17M-$-93.87M-$-88.7M
EPSd-$-1.87M-$-5.59M-$-17.06M-$-44.28M-$-103.14M
Operating cash flow-$-85.62M-$-130.9M-$-96.51M-$-77.1M-$-70.91M
Capital expenditure-$-3M-$-7.33M-$-60K-$-100K-$-610K
Free cash flow-$-88.62M-$-138.23M-$-96.57M-$-77.2M-$-71.52M
Total assets$290.5M$146.5M$147.3M$155.6M$117.2M
Total debt$77.3M$78.1M$58.3M$38.4M$39.8M
Net debt-$-139.76M$22.4M-$-40.94M-$-83.3M-$-42M
Total equity$186.3M$22.2M$51.1M$74.1M$64.4M
Cash and short-term investments$253M$102.1M$114.2M$121.7M$81.8M
Income statement
20252024202320222021
Revenue$35.1M$2.56M$0.00$0.00$0.00
Cost of revenue$6.26M$800K$0.00$0.00$1.89M
Gross profit$28.9M$1.76M$0.00$0.00-$-1.89M
Research and development expenses$72.2M$81.6M$72M$61.1M$48.8M
Selling, general and administrative expenses$43.5M$61.5M$35.5M$27M$24.7M
Other expenses$0.00-$-105M$0.00-$-510K$0.00
Operating expenses$115.7M$38.2M$107.5M$87.6M$73.5M
Cost and expenses$122M$39M$107.5M$87.6M$75.4M
Interest income$4.58M$5.77M$4.58M$220K$10K
Interest expense$8.88M$8.77M$5.78M$3.99M$3.64M
Depreciation and amortization$1.28M$800K$420K$510K$1.89M
Ebitda-$-69M-$-27.58M-$-94.89M-$-89.33M-$-83.14M
Operating income-$-86.88M-$-36.4M-$-107.52M-$-87.57M-$-75.35M
Total other income/expenses, net$7.72M-$-740K$6.43M-$-6.27M-$-13.33M
Income before tax-$-79.16M-$-37.14M-$-101.09M-$-93.84M-$-88.68M
Income tax expense$40K$310K$80K$30K$20K
Net income-$-79.2M-$-37.45M-$-101.17M-$-93.87M-$-88.7M
Weighted average shares outstanding$42.3M$6.7M$5.93M$2.12M$860K
Weighted average diluted shares outstanding$42.3M$6.7M$5.93M$2.12M$860K
Balance sheet
20252024202320222021
Cash and short-term investments$253M$102.1M$114.2M$121.7M$81.8M
Net receivables$570K$1.71M$560K$1.15M$750K
Inventory$4.48M$2.82M$0.00$0.00$0.00
Total current assets$261.6M$112.2M$122.1M$128.7M$87.9M
Property, plant and equipment, net$1.59M$4.84M$6.39M$8.33M$10.2M
Goodwill and intangible assets$26.6M$27.4M$17.4M$17.4M$17.4M
Long-term investments$0.00$0.00$0.00$0.00$1.32M
Total non-current assets$28.9M$34.3M$25.2M$26.9M$29.3M
Total assets$290.5M$146.5M$147.3M$155.6M$117.2M
Accounts payable$5.7M$8.62M$8.95M$7.78M$4.28M
Short-term debt$990K$1.25M$1.1M$2.51M$1.87M
Deferred revenue$460K$0.00$0.00$0.00$0.00
Total current liabilities$25.8M$32.9M$22.9M$22.3M$14M
Long-term debt$76.3M$76.8M$57.2M$35.9M$37.9M
Deferred revenue, non-current$620K$0.00$0.00$0.00$0.00
Total non-current liabilities$78.4M$91.4M$73.3M$59.2M$38.7M
Capital lease obligations$990K$2.66M$3.71M$4.8M$4.78M
Total liabilities$104.2M$124.3M$96.2M$81.5M$52.8M
Common stock$90K$10K$170K$120K$30K
Retained earnings-$-594.55M-$-515.36M-$-477.9M-$-376.74M-$-282.87M
Accumulated other comprehensive income (loss)-$-110K-$-120K-$-120K-$-120K-$-120K
Total equity$186.3M$22.2M$51.1M$74.1M$64.4M
Total investments$36M$46.4M$15M$0.00$1.32M
Total debt$77.3M$78.1M$58.3M$38.4M$39.8M
Net debt-$-139.76M$22.4M-$-40.94M-$-83.3M-$-42M
Cash flow statement
20252024202320222021
Net income-$-79.2M-$-37.45M-$-101.17M-$-93.87M-$-88.7M
Depreciation and amortization$1.28M$800K$420K$510K$1.89M
Stock-based compensation$4.3M$8.2M$8.69M$5.2M$0.00
Change in working capital-$-2.58M$2.67M$340K$5.74M-$-1.5M
Accounts receivable$500K-$-1.07M$0.00$0.00$0.00
Inventory-$-1.66M-$-2.82M$0.00$0.00$0.00
Accounts payable-$-2.98M-$-290K$1.23M$3.42M$1.17M
Net cash provided by operating activities-$-85.62M-$-130.9M-$-96.51M-$-77.1M-$-70.91M
Investments in property, plant and equipment-$-3M-$-330K-$-60K-$-100K-$-610K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$8.15M$67M-$-14.88M-$-100K-$-610K
Common stock issued$238.5M$290K$60M$122.6M$76.3M
Common stock repurchased$0.00$0.00$0.00$0.00-$-2M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$238.6M$20.3M$88.5M$117.2M$74.3M
Net change in cash$161.4M-$-43.77M-$-22.78M$39.9M$2.81M
Cash at end of period$217.9M$56.5M$100.3M$123M$81.8M
Operating cash flow-$-85.62M-$-130.9M-$-96.51M-$-77.1M-$-70.91M
Capital expenditure-$-3M-$-7.33M-$-60K-$-100K-$-610K
Free cash flow-$-88.62M-$-138.23M-$-96.57M-$-77.2M-$-71.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About X4 Pharmaceuticals, Inc.

        X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

        CEO
        Adam R. Craig
        Employees
        45
        Beta
        0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of X4 Pharmaceuticals, Inc. (XFOR)?

        InvestorsCraft does not currently publish an intrinsic value for XFOR. How the IC value is calculated.

        Is XFOR undervalued?

        InvestorsCraft does not publish an undervaluation signal for XFOR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.